These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 9493602

  • 1. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T, Hori T, Moriike M, Asano T, Hayashi H, Iwade K, Hosoda S.
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
    Lynch JJ, Sitko GR, Lehman ED, Vlasuk GP.
    Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV, Crowe VG, Frank JD, Wilson HC, Coffman WJ, Utterback BG, Jakubowski JA, Smith GF.
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [Abstract] [Full Text] [Related]

  • 5. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S, Tschopp T, Baumgartner HR.
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [Abstract] [Full Text] [Related]

  • 6. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, Sanderson PE, Vacca JP, Shafer JA, Lynch JJ.
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [Abstract] [Full Text] [Related]

  • 7. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW.
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G, Pascucci C, Cosmi B, Nenci GG.
    Thromb Haemost; 1990 Apr 12; 63(2):204-7. PubMed ID: 2363121
    [Abstract] [Full Text] [Related]

  • 18. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis].
    Ju CW, Wang LS, Yang X, Ma GS, Hua ZC, Gao XY.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep 12; 25(9):540-3. PubMed ID: 15569533
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.
    J Pharmacol Exp Ther; 2005 Aug 12; 314(2):710-6. PubMed ID: 15860572
    [Abstract] [Full Text] [Related]

  • 20. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.